The use of tyrosine kinase inhibitors (TKIs) to treat chronic myeloid leukemia (CML)
represents the paradigm for modern targeted cancer therapy. Importantly, molecular …

Molecular monitoring plays an essential role in the clinical management of chronic myeloid
leukemia (CML) patients, and now guides clinical decision making. Quantitative reverse …

With the advent of tyrosine kinase inhibitors (TKIs), the goals of therapy in chronic myeloid
leukemia (CML) are steadily shifting. Long-term disease control on TKI therapy has been the …

ABSTRACT Introduction: Fusion of BCR-ABL1 genes causes chronic myeloid leukemia
(CML). As a reliable marker of disease burden, it also serves as the target of tyrosine kinase …

Tyrosine kinase inhibitor (TKI) therapy yields sustained cytogenetic remissions in most
patients with chronic‐phase chronic myeloid leukemia (CML). Peripheral blood quantitative …

Chronic myeloid leukemia (CML) is the paradigm for targeted cancer therapy. RT-qPCR is
the gold standard for monitoring response to tyrosine kinase-inhibitor (TKI) therapy based on …

Major Molecular Response in CML Patients Treated with Tyrosine Kinase Inhibitors: The
Paradigm for Monitoring Targeted Cancer Therapy | The Oncologist | Oxford Academic Skip to …

The pathognomonic genetic alteration in chronic myeloid leukemia is the formation of the
BCR-ABL1 fusion gene, which produces a constitutively active tyrosine kinase that drives …

BACKGROUND Tyrosine kinase inhibitors (TKIs) are the cornerstone of successful clinical
management of patients with chronic myeloid leukemia (CML). Quantitative monitoring of the …

Chronic myeloid leukemia (CML) is a hematological disease accounting for about 15-20% of
all adult leukemias. The clinical and biologic advances achieved in such a malignancy …